This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

GE Healthcare: DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging Demonstrates Impact On The Diagnosis And Clinical Management Of Patients With Clinically Uncertain Parkinsonian Syndrome

Stocks in this article: GE

GE Healthcare today presented the results of a randomized study analyzing the effect of DaTscan™ (Ioflupane I 123 Injection) SPECT imaging in a group of adult patients with clinically uncertain parkinsonian syndromes (CUPS) as part of 1-year follow up from imaging baseline. It was the first world-wide prospective trial including US experience, using selected endpoints in patients with CUPS. The findings, presented at the 2012 American Academy of Neurology Meeting, showed significant differences in clinical management, diagnosis, and physician confidence of diagnosis (CoD) for a group of patients with CUPS who had been imaged with DaTscan. 1

DaTscan is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected parkinsonian syndromes (PS). DaTscan may be used to help differentiate essential tremor from tremor due to PS (idiopathic Parkinson’s disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP)). DaTscan is an adjunct to other diagnostic evaluations. DaTscan was not designed to distinguish among PD, MSA and PSP. The effectiveness of DaTscan as a screening or confirmatory test and for monitoring disease progression or response to therapy has not been established.

This multi-center, randomized, open-label global (19 university hospital centers in US and Europe) clinical trial compared the clinical management, diagnosis and CoD of patients with CUPS who underwent DaTscan imaging (N=135) with those in the control group who did not (N=138). The full study evaluated patients at four weeks, 12 weeks and 52 weeks from baseline; imaging in the DaTscan group was performed 1 to 4 weeks from baseline. Results showed that significantly more patients in the DaTscan imaging group had at least one change in their clinical management from their baseline after 12 weeks (p = 0.002) and after 1 year (p < 0.001) compared with patients in the control group. Additionally, significantly more DaTscan imaging patients had a change from baseline in diagnosis and their physicians expressed greater CoD at all visits (all p < 0.001) compared with physicians of control patients.. In the DaTscan group, change in diagnosis at 1 year was found to be significantly higher among general neurologists (75%) compared with movement disorder specialists (47%; p<0.05 ). DaTscan was safe and well-tolerated in this trial. 1 In clinical trials, headache, nausea, vertigo, dry mouth or dizziness of mild to moderate severity were reported. In post-marketing experience, hypersensitivity reactions and injection site pain have been reported.

“These results show that in diagnosing patients experiencing symptoms of clinically uncertain PS, DaTscan may be clinically useful in helping neurologists and movement disorder specialists who may have difficulty confidently diagnosing patients using a clinical exam and other diagnostic tests,” said Igor Grachev, MD, PhD, Global Head of DaTscan, Medical Affairs, GE Healthcare, Medical Diagnostics who was a medical director for this trial. “In addition, physicians of patients who undergo the procedure may have greater confidence in their diagnoses, which may enable them to make more informed treatment decisions to better support and advise their patients.”

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs